Anti-CD123 ADC and PARP Inhibitor Combination for AML
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for relapsed or refractory hematological malignancies, particularly those targeting CD123, require enhanced efficacy to effectively manage cancers such as acute myeloid leukemia (AML) and other hematological cancers.
Innovation Solution
A combination therapy involving an anti-CD123 antibody-drug conjugate, such as IMGN632, paired with a poly ADP ribose (PARP) inhibitor like olaparib or talazoparib, which targets and induces cancer cell death by enhancing DNA damage and cell cycle arrest.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If an anti-CD123 antibody-drug conjugate is used to treat relapsed or refractory hematological malignancies, then the treatment targets CD123-positive cancer cells, but the efficacy is insufficient for relapsed or refractory cases
Solution Approach 1:
The patent combines an anti-CD123 antibody-drug conjugate with a PARP inhibitor to create a combination therapy. The antibody-drug conjugate delivers cytotoxic agents specifically to CD123-positive cancer cells, while the PARP inhibitor blocks DNA repair mechanisms. This merging of two therapeutic mechanisms produces synergistic effects that overcome resistance in relapsed or refractory hematological malignancies, achieving higher cancer cell death rates than either agent alone.
2Reliability
If a PARP inhibitor is added to enhance DNA damage in cancer cells, then the synergistic anti-leukemic effects are improved, but the treatment complexity increases
Solution Approach 1:
The patent merges two pharmacologically distinct agents—the anti-CD123 antibody-drug conjugate and the PARP inhibitor—into a unified treatment regimen. This combination leverages complementary mechanisms of action: the antibody-drug conjugate provides targeted cytotoxicity while the PARP inhibitor creates synthetic lethality by blocking DNA repair. The synergistic interaction between these agents enhances anti-leukemic effects without requiring complex multi-agent chemotherapy protocols.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy demonstrates synergistic anti-leukemic effects, significantly improving treatment outcomes by inducing apoptosis and cell cycle arrest in AML cells, including relapsed and refractory cases, beyond the efficacy of monotherapy.
Implementation Method 1
an anti-CD123 antibody-drug conjugate
Implementation Method 2
a poly ADP ribose (PARP) inhibitor
Data Source
AI summary
A composition including an anti-CD123 antibody-drug conjugate and a poly ADP ribose (PARP) inhibitor can be used in therapy or as a medicament. The composition including the anti-CD123 antibody-drug conjugate and the poly ADP ribose (PARP) inhibitor can be used for treating cancer or for inducing cancer cell death in a population of cancer cells. Hematological cancers such as acute myeloid leukemia (AML) can be treated with the composition. Administering an anti-CD123 antibody-drug conjugate and a poly ADP ribose (PARP) inhibitor is a method of treating cancer. Administering, to a population of cancer cells, an anti-CD123 antibody-drug conjugate and a poly ADP ribose (PARP) inhibitor is a method for inducing cancer cell death.